Predecessor Gene Guselli to Retire from Day-to-Day Operation, Will
Remain as Advisor
NEEDHAM, Mass.–(BUSINESS WIRE)–BostonSight,
an international leader in the treatment of patients with complex
corneal disease, today announced that its CFO, Sara Yost, will be
promoted to CEO effective March 11, 2019. She will replace current
President and CEO Gene Guselli, who is retiring. Guselli will assist
with the transition and remain with BostonSight as an Advisor through
the end of 2019.
Gene Guselli joined BostonSight as President and CEO in April 2016. With
over 30 years of experience pioneering innovations in healthcare, Gene
lead the successful launch of BostonSight SCLERAL, helping to deliver
unparalleled scleral lens design for doctors and patients.
Sara Yost has been with BostonSight since 2002, holding several
positions in administration, finance and operations, including the past
three years as CFO. Yost has a BS in Health Management and Policy from
the University of New Hampshire and earned an MBA, High Distinction,
Accounting from Bentley University. As CEO, she will be focused on
expanding the availability of BostonSight’s PROSE
products, with a near-term emphasis on international expansion.
“Sara’s unparalleled knowledge of the BostonSight organization and
industry, coupled with the deep relationships she has formed with its
employees and network partners made Sara the ideal choice to succeed
Gene as CEO,” said David Rosenbloom, PhD, Chairman of the Board at
BostonSight. “The Board would like to thank Gene for his tremendous
contributions as President and CEO these last three years. He has helped
build an operational and strategic foundation that will allow us to
aggressively pursue our objectives in the coming years.”
BostonSight is an internationally renowned nonprofit eye healthcare
organization with a mission to improve the quality of life for patients
and their families by transforming the understanding, treatment and care
of the ocular surface. For more information, visit www.bostonsight.org.